Investors Hub Daily
iHub My Stocks Activity
Ticker Buzz Cloud
Most Followed Members
Hot on StockWiki
My Image Gallery
Market Trends and Strategies
$heff's $tation of $tocks & $olid DD
PATH:NuPathe to Present at the Safeguard Scientifics Investor
Post New Msg
Monday, October 08, 2012 7:27:27 AM
PATH:NuPathe to Present at the Safeguard Scientifics Investor Day 2012
CONSHOHOCKEN, PA--(Marketwire - Oct 8, 2012) - NuPathe Inc. ( NASDAQ : PATH ), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Armando Anido, chief executive officer, will present a company overview at the Safeguard Scientifics Investor Day 2012 at The Yale Club of New York City on Tuesday, October 9, 2012 at approximately 10:30 am EDT.
To listen to the live call, please dial 877-317-6789 (domestic) or +1-412-317-6789 (international), approximately 10 minutes before the presentation time, or go to www.safeguard.com/InvestorDay2012 for the live webcast. A replay of the call and webcast will be available through November 9, 2012 at 9:00 am ET. Investors may listen to the replay of the call by dialing 877-344-7529 (domestic) or +1-412-317-0088 (international), with the replay access code of 10019309.
A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on NuPathe's website through November 9, 2012 at 9:00 am ET.
If you are interested in attending or for additional information, please visit Safeguard's microsite at www.safeguard.com/InvestorDay2012.
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for its product candidates in the U.S. and territories throughout the world.
For more information about NuPathe, please visit our website and our blog at www.nupathe.com. You can also follow us on StockTwits (stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare (slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com).
Post New Msg
Report TOS Violation
+/- to Watchlist
© 2013 InvestorsHub.Com, Inc.
Terms of Service
Advertise With Us
Stock Market 101
Investor Help Forum
iHub on Facebook
iHub on Twitter
iHub iPhone/iPad App
iHub Android App